According to Meihua Biotech's announcement, it is expected to achieve net profit of 600 million yuan to 800 million yuan in the semi-annual year of 2026. Compared with 1,768 billion yuan in the same period last year, it is expected to decrease 970 million yuan to 1,170 million yuan, a year-on-year decrease of 55% to 66%; net profit after deducting non-recurring profit and loss of 430 million yuan to 630 million yuan, a year-on-year decrease of 61% to 74%. The pre-decline in performance was mainly due to an increase in industry supply and a year-on-year decline in the prices of the company's main products.

According to Meihua Biotech's announcement, it is expected to achieve net profit of 600 million yuan to 800 million yuan in the semi-annual year of 2026. Compared with 1,768 billion yuan in the same period last year, it is expected to decrease 970 million yuan to 1,170 million yuan, a year-on-year decrease of 55% to 66%; net profit after deducting non-recurring profit and loss of 430 million yuan to 630 million yuan, a year-on-year decrease of 61% to 74%. The pre-decline in performance was mainly due to an increase in industry supply and a year-on-year decline in the prices of the company's main products.